Dr. Paul Rubin joined Xoma in June of 2011. Prior to XOMA, Dr. Rubin was CMO at Funxional Therapeutics, CEO of Resolvyx Pharmaceuticals and President and CEO of Critical Therapeutics. Dr. Rubin served as SVP, Development, and later as EVP, Research & Development at Sepracor. He was responsible for the development of approved products including Xopenex®, Lunesta®, Xopenex HFA® and Brovana®. Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as VP of Worldwide Clinical Pharmacology and Early Clinical Development. At Abbott, Dr. Rubin served as VP, Immunology and Endocrinology, where he advanced zilueton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.